Clinical trials: Small Cell Lung Cancer
Lung Cancer (NSCLC)
Surgical Outcome Of da Vinci Single-port Surgical System In Lung Cancer
Early-stage lung cancer represents a clinical challenge that, when diagnosed promptly, offers high chances of cure through lobectomy and lymphadenectomy.
- Trial name
- NCT07790406
- Testing
- da Vinci Single Port
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- European Institute of Oncology
Carcinoma, Non-Small-Cell Lung
Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA)
First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy in Asia Area
- Trial name
- NCT04529564
- Where
- 12 sites in Taiwan
- Volunteers
- 106 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer (NSCLC)
Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1
Importance: EGFR tyrosine kinase inhibitors (EGFR-TKIs) and PD-1/PD-L1 immune checkpoint inhibitors are widely used in the treatment of non-small cell lung cancer (NSCLC).
- Trial name
- NCT07036016
- Testing
- EGFR-TKI, PD-1/PD-L1 inhibitor, EGFR-TKI combined with PD-1/PD-L1
- Volunteers
- 67,818 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Carcinoma, Non-Small-Cell Lung, Neoadjuvant Immunotherapy
Comparison of the Effect of Surgical Resection Based on Lesion Extent Before and After Neoadjuvant Therapy in Patients With Stage II-IIIB Non-Small Cell Lung Cancer: A Single-Center, Real-World, Open-Label Study
This study intends to conduct a prospective, non-interventional study to compare the survival benefits of different surgical resection patterns for patients with non-small cell lung cancer who have achieved partial response (PR)…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Neoadjuvant Immunotherapy, Surgery
- Trial name
- NCT07373899
- Where
- China
- Volunteers
- 354 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lung Cancer
Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, carboplatin, and paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00016315
- Testing
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 19 sites in United States
- Volunteers
- 35 people
- Sponsor
- Radiation Therapy Oncology Group
Lung Cancer Stage IV, Lung Cancer, Non-small Cell
Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.
Immune-checkpoint inhibitors have recently become available as a new therapy for a variety of cancers. This drugs function by boosting the anti-cancer immune response, but unfortunately, may cause off-target, non-specific immune…
- Conditions
- Lung Cancer Stage IV, Lung Cancer, Non-small Cell, Hepatitis
- Trial name
- NCT04595734
- Testing
- No intervention due to observational methods of study
- Where
- 3 sites in Australia
- Volunteers
- 500 people
- Sponsor
- Western Sydney Local Health District
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer
2-Drug Combination Chemotherapy Followed by Radiotherapy. Paclitaxel, TAX, NSC-125973; Cisplatin, CDDP, NSC-119875; followed by chest irradiation using 4-15 MV photons.
- Trial name
- NCT00001499
- Testing
- paclitaxel, cisplatin, chest radiotherapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Iressa/Docetaxel in Non-Small-Cell Lung Cancer
Patients will receive 250 mg Iressa by mouth daily each day while on this study. Patients will also receive docetaxel 30 mg/m2 by by vein (IV) on day 1 weekly for the first 3 weeks of each course of therapy.
- Trial name
- NCT00048087
- Testing
- ZD1839, Docetaxel
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Melanoma, Non-Small-Cell Lung Cancer
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors.
- Conditions
- Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma
- Trial name
- NCT05355701
- Testing
- PF-07799933, binimetinib, cetuximab
- Where
- 40 sites in United States, Canada and 1 more
- Volunteers
- 103 people
- Sponsor
- Pfizer
NSCLC, ALCL
Crizotinib Continuation Clinical Study
The purpose of this continuation study is to provide continued access to crizotinib treatment for eligible participants from a current Pfizer sponsored crizotinib clinical study that is planned to close.
- Conditions
- NSCLC, ALCL, IMT
- Trial name
- NCT05160922
- Testing
- crizotinib
- Where
- 13 sites in China, Italy and 3 more
- Volunteers
- 27 people
- Sponsor
- Pfizer
NSCLC (Advanced Non-small Cell Lung Cancer)
A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This is a Randomized, Double-Blind, Multicenter, Phase II/III Study to Evaluate HLX37 (Recombinant Human Anti-PD-L1 and Anti-VEGF Bispecific Antibody) in Combination with Chemotherapy Versus Pembrolizumab in Combination with…
- Trial name
- NCT07865910
- Testing
- Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion)
- Where
- 16 sites in China
- Volunteers
- 1,438 people
- Sponsor
- Shanghai Henlius Biotech
Non-small Cell Lung Cancer
Study on the Association of GSTP1 and Other Gene Polymorphisms With Platinum-induced Myelosuppression
This study intends to design a retrospective and prospective, cohort study to explore the association between genetic polymorphism of GSTP1 A313G rs1695 or others and adverse effects of platinum drugs, aiming to explore the risk…
- Trial name
- NCT06140082
- Testing
- GSTP1 A313G （AA）
- Volunteers
- 477 people
- Sponsor
- LI YAN
Advanced Endstage Solid Carcinomas in Adults
CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors
To assess the anti-tumor activity of CAP7.1 based on the observed objective response rate and rate of disease stabilization, as defined by the below primary and secondary endpoints, in patients with Non-Small Cell Lung Carcinoma…
- Trial name
- CAP7-1 (NCT02094560)
- Testing
- CAP7.1
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- CellAct Pharma GmbH
Brain and Central Nervous System Tumors, Intraocular Melanoma
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00003022
- Testing
- iodine I 131 monoclonal antibody 3F8
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer
Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)
Multinational, multi-center medical record review to describe the treatment patterns, clinical outcomes, and EGFR / T790M testing practices in EGFR-mutated advanced NSCLC patients receiving first-line EGFR TKI therapy in Europe.
- Trial name
- REFLECT (NCT04031898)
- Testing
- Non Interventional
- Where
- Bulgaria
- Volunteers
- 896 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Efficacy of Re-challenge With Immune-Checkpoints Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients: a Retrospective Observational Study
This is a multicentre, retrospective, national observational study aiming to describe clinical outcomes of advanced NSCLC patients that performed an ICP re-challenge during their history of disease.
- Trial name
- RE-CHALLENGE (NCT04069663)
- Testing
- No interventional study
- Where
- France
- Volunteers
- 144 people
- Sponsor
- University Hospital, Grenoble
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Colorectal Cancer
Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer
RATIONALE: Diagnostic procedures, such as positron emission tomography/computed tomography (PET/CT) scanning before surgery, may help measure the extent of disease.
- Conditions
- Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head and Neck Cancer
- Trial name
- NCT01254591
- Testing
- 18F-fluoromisonidazole, fluorescence angiography, laboratory biomarker analysis
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- University College London (UCL) Cancer Institute
Lung Cancer
Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of rebeccamycin analogue is more effective in treating non-small cell lung…
- Trial name
- NCT00006017
- Testing
- becatecarin
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Case Comprehensive Cancer Center